These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 491396)

  • 1. Reversal of hyperparathyroidism in response to dietary phosphorus restriction in the uremic dog.
    Kaplan MA; Canterbury JM; Bourgoignie JJ; Veliz G; Gavellas G; Reiss E; Bricker NS
    Kidney Int; 1979 Jan; 15(1):43-8. PubMed ID: 491396
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol.
    Lopez-Hilker S; Dusso AS; Rapp NS; Martin KJ; Slatopolsky E
    Am J Physiol; 1990 Sep; 259(3 Pt 2):F432-7. PubMed ID: 2396669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrelations between phosphorus, calcium, parathyroid hormone, and renal phosphate excretion in response to an oral phosphorus load in normal and uremic dogs.
    Kaplan MA; Canterbury JM; Gavellas G; Jaffe D; Bourgoignie JJ; Reiss E; Bricker NS
    Kidney Int; 1978 Sep; 14(3):207-14. PubMed ID: 723149
    [No Abstract]   [Full Text] [Related]  

  • 4. Interrelations between phosphorus, calcium, parathyroid hormone, and phosphate excretion in the normal and uremic dog.
    Kaplan MA; Canterbury JM; Gavellas G; Reiss E; Bricker NS
    Adv Exp Med Biol; 1978; 103():257-62. PubMed ID: 717109
    [No Abstract]   [Full Text] [Related]  

  • 5. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake.
    Slatopolsky E; Caglar S; Gradowska L; Canterbury J; Reiss E; Bricker NS
    Kidney Int; 1972 Sep; 2(3):147-51. PubMed ID: 4669450
    [No Abstract]   [Full Text] [Related]  

  • 6. Famotidine reduces serum parathyroid hormone levels in uremic patients.
    Arik N; Arinsoy T; Sayín M; Taşdemir I; Yasavul U; Turgan C; Caglar S
    Nephron; 1991; 59(2):333. PubMed ID: 1956503
    [No Abstract]   [Full Text] [Related]  

  • 7. Reversal of hyperparathyroidism in severe uremics following very low-protein and low-phosphorus diet.
    Barsotti G; Morelli E; Guiducci A; Ciardella F; Giannoni A; Lupetti S; Giovannetti S
    Nephron; 1982; 30(4):310-3. PubMed ID: 7110461
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcium and phosphorus metabolism in chronic uremia.
    Fiaschi E; Mioni G; Maschio G; D'Angelo A; Ossi E
    Nephron; 1975; 14(2):163-80. PubMed ID: 1093055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs.
    Jacob AI; Canterbury JM; Gavellas G; Lambert PW; Bourgoignie JJ
    J Clin Invest; 1981 Jun; 67(6):1753-60. PubMed ID: 7240419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease.
    Slatopolsky E; Bricker NS
    Kidney Int; 1973 Aug; 4(2):141-5. PubMed ID: 4355426
    [No Abstract]   [Full Text] [Related]  

  • 11. Calcium and phosphorus metabolism and bone disease in uremia.
    Kleeman CR; Massry SG; Coburn JW; Popovtzer MM
    Clin Orthop Relat Res; 1970; 68():210-37. PubMed ID: 4905786
    [No Abstract]   [Full Text] [Related]  

  • 12. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis".
    Bricker NS
    N Engl J Med; 1972 May; 286(20):1093-9. PubMed ID: 4553202
    [No Abstract]   [Full Text] [Related]  

  • 13. Phosphorus intake regulates intestinal function and polyamine metabolism in uremia.
    Imanishi Y; Koyama H; Inaba M; Okuno S; Nishizawa Y; Morii H; Otani S
    Kidney Int; 1996 Feb; 49(2):499-505. PubMed ID: 8821836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat.
    Felsenfeld AJ; Machado L; Bover J; Trinidad P; Rodriguez M
    Nephrol Dial Transplant; 1993; 8(4):325-34. PubMed ID: 8390007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of calcium and phosphorus on patients maintained on dialysis.
    Goldsmith RS; Arnaud CD; Johnson WJ
    Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
    [No Abstract]   [Full Text] [Related]  

  • 16. "Magnification phenomenon" in chronic renal disease.
    Bricker NS; Fine LG; Kaplan M; Epstein M; Bourgoignie JJ; Light A
    N Engl J Med; 1978 Dec; 299(23):1287-93. PubMed ID: 714096
    [No Abstract]   [Full Text] [Related]  

  • 17. Calcium, phosphorus and vitamin D disorders in uremia.
    Slatopolsky E; Brown A; Dusso A
    Contrib Nephrol; 2005; 149():261-271. PubMed ID: 15876849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy.
    Maschio G; Tessitore N; D'Angelo A; Bonucci E; Lupo A; Valvo E; Loschiavo C; Fabris A; Morachiello P; Previato G; Fiaschi E
    Am J Clin Nutr; 1980 Jul; 33(7):1546-54. PubMed ID: 7395775
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary hyperparathyroidism in patients with chronic kidney failure].
    Fillastre JP; Robert M; Dubois D
    Sem Hop; 1973 Feb; 49(7):501-6. PubMed ID: 4350601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.